MD20160027A2 - Terapii imuno-oncolitice - Google Patents
Terapii imuno-oncoliticeInfo
- Publication number
- MD20160027A2 MD20160027A2 MDA20160027A MD20160027A MD20160027A2 MD 20160027 A2 MD20160027 A2 MD 20160027A2 MD A20160027 A MDA20160027 A MD A20160027A MD 20160027 A MD20160027 A MD 20160027A MD 20160027 A2 MD20160027 A2 MD 20160027A2
- Authority
- MD
- Moldova
- Prior art keywords
- immunity
- reduces
- gene
- antibody response
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Prezenta invenţie se referă la virusuri oncolitice de vaccin variolic, modificate pentru a stimula imunitatea antitumorală şi/sau a diminua imunitatea gazdei şi/sau răspunsul anticorpilor gazdei împotriva virusului. Aceasta se bazează, cel puţin în parte, pe descoperirea că virusul oncolitic de vaccin variolic (i) purtând o deleţie genomică a genei, reduce imunitatea celulelor T (proteina de legare a interleucinei-18); (ii) tratat cu enzima sialidază, se consideră că reduce activarea TLR2 şi, astfel, răspunsul anticorpilor; (iii) poartă gena care amplifică inducerea limfocitelor T citotoxice (de exemplu, TRIF) şi/sau (iv) reduce numărul de celule tumorale supresoare de origine mieloidă prin reducerea cantităţii de prostaglandină E2, ce duce la reducerea creşterii tumorii. Astfel, prezenta invenţie se referă la virusuri imunooncolitice de vaccin variolic şi la metode de utilizare a acestora în tratamentul tumorilor maligne.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361868978P | 2013-08-22 | 2013-08-22 | |
PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20160027A2 true MD20160027A2 (ro) | 2016-08-31 |
MD4624B1 MD4624B1 (ro) | 2019-03-31 |
MD4624C1 MD4624C1 (ro) | 2019-10-31 |
Family
ID=52484194
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MD20160027A MD4624C1 (ro) | 2013-08-22 | 2014-08-22 | Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice |
MDA20180086A MD4748C1 (ro) | 2013-08-22 | 2014-08-22 | Terapii imunooncolitice |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20180086A MD4748C1 (ro) | 2013-08-22 | 2014-08-22 | Terapii imunooncolitice |
Country Status (26)
Country | Link |
---|---|
US (2) | US11478518B2 (ro) |
EP (3) | EP4324918A3 (ro) |
JP (3) | JP6912199B2 (ro) |
KR (1) | KR102389240B1 (ro) |
CN (1) | CN105658795B (ro) |
AU (1) | AU2014308648B2 (ro) |
CA (3) | CA2921041C (ro) |
DK (2) | DK3778897T3 (ro) |
EA (1) | EA037582B1 (ro) |
ES (2) | ES2847305T3 (ro) |
FI (1) | FI3778897T3 (ro) |
HK (1) | HK1223402A1 (ro) |
HR (1) | HRP20240078T1 (ro) |
IL (1) | IL243996A0 (ro) |
LT (1) | LT3778897T (ro) |
MD (2) | MD4624C1 (ro) |
MX (1) | MX2016002257A (ro) |
NZ (1) | NZ716825A (ro) |
PE (1) | PE20160673A1 (ro) |
PH (1) | PH12016500329A1 (ro) |
PL (1) | PL3778897T3 (ro) |
PT (1) | PT3778897T (ro) |
RS (1) | RS65104B1 (ro) |
SG (1) | SG11201600960PA (ro) |
SI (1) | SI3778897T1 (ro) |
WO (1) | WO2015027163A1 (ro) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3778897T (lt) | 2013-08-22 | 2024-02-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Imunoonkolitinės terapijos |
WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
EP3327137B1 (en) * | 2015-07-22 | 2020-12-09 | National University Corporation Tottori University | Host regulation factor for enhancing proliferation and propagation of vaccinia virus |
US10646524B2 (en) | 2015-09-08 | 2020-05-12 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof |
EP3371221A2 (en) | 2015-11-07 | 2018-09-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
CN116440176A (zh) | 2016-02-25 | 2023-07-18 | 纪念斯隆凯特琳癌症中心 | 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
MX2018010231A (es) | 2016-02-25 | 2019-06-06 | Memorial Sloan Kettering Cancer Center | Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos. |
CN109152736A (zh) * | 2016-03-25 | 2019-01-04 | 联邦高等教育系统匹兹堡大学 | 合成包封病毒 |
EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
KR102619496B1 (ko) * | 2016-07-19 | 2023-12-29 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Stat3를 타겟으로 하는 종양용해성 바이러스 |
WO2018057755A1 (en) * | 2016-09-21 | 2018-03-29 | Thorne Stephen H | High mobility group box i mutant |
GB201616365D0 (en) | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
CA3052463A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
EP3593136A1 (en) * | 2017-03-06 | 2020-01-15 | Talaris Therapeutics, Inc. | Methods and compositions for determining the potency of a therapeutic cellular composition |
ES2971065T3 (es) * | 2017-04-21 | 2024-06-03 | Sillajen Inc | Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control |
CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
EP3703723A4 (en) * | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
JP2021503965A (ja) | 2017-12-01 | 2021-02-15 | スッター,ゲルド | 複製効率の高い免疫調節ワクシニアウイルス株 |
SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
CA3106983A1 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
PE20212307A1 (es) * | 2018-12-21 | 2021-12-10 | Ottawa Hospital Res Inst | Vectores de orthopoxvirus modificados |
CA3125020A1 (en) * | 2019-01-07 | 2020-07-16 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
TW202038994A (zh) * | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
EP3923967A1 (en) | 2019-02-14 | 2021-12-22 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
EP4045657A4 (en) * | 2019-10-16 | 2023-11-15 | KaliVir Immunotherapeutics, Inc. | MODIFIED EXTRACELLULAR ENVELOPED VIRUS |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
JP2021106576A (ja) * | 2019-12-12 | 2021-07-29 | イグナイト・イミュノセラピー,インコーポレーテッド | 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法 |
AU2021205287A1 (en) * | 2020-01-09 | 2022-07-21 | Pfizer Inc. | Recombinant vaccinia virus |
JP2024516400A (ja) * | 2021-04-30 | 2024-04-15 | カリヴィル イムノセラピューティクス, インコーポレイテッド | 修飾されたmhc発現のための腫瘍溶解性ウイルス |
EP4363059A1 (en) * | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2269618A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer. |
WO2007023725A1 (ja) * | 2005-08-25 | 2007-03-01 | Yokohama City University | 遺伝子ワクチン |
AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
KR20090004839A (ko) * | 2005-09-07 | 2009-01-12 | 제네렉스, 인코포레이티드 | Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법 |
KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
US20110038843A1 (en) * | 2008-03-31 | 2011-02-17 | Kusmartsev Sergei A | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
DK2477499T3 (en) | 2009-09-14 | 2018-06-06 | Sillajen Biotherapeutics Inc | COMBINATION CANCER THERAPY WITH ONCOLYTIC VACCINIA VIRUS |
US20130202639A1 (en) | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
EP2697368B1 (en) * | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
LT3778897T (lt) | 2013-08-22 | 2024-02-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Imunoonkolitinės terapijos |
-
2014
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active IP Right Grant
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en active Pending
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en active Application Filing
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
- 2016-10-12 HK HK16111742.0A patent/HK1223402A1/zh unknown
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US20230008089A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500329A1 (en) | Immuno-oncolytic therapies | |
PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
PH12017501942A1 (en) | Oncolytic adenovirus encoding a b7 protein | |
MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
MD4655C1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
MX2017004691A (es) | Bloqueo de cd73. | |
BR112017003108A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
MX2015015638A (es) | Metodos para diseñar celulas t altamente activas para inmunoterapia. | |
MX2018004600A (es) | Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. | |
AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
MX2021008392A (es) | Neoantígenos prostaticos y sus usos. | |
EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
EA201991806A1 (ru) | Опухоль-селективные мутанты tata-бокса и caat-бокса | |
WO2018017747A3 (en) | Oncolytic viruses targeting stat3 | |
EA201990593A1 (ru) | Непрерывный способ для снижения гетерогенности терапевтического белка | |
MD4480B1 (ro) | Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia | |
MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. | |
WO2019202401A3 (en) | Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer | |
EA201790360A1 (ru) | Получение полностью процессированного и функционального фактора x в фурин-секретирующей системе экспрессии млекопитающего | |
PH12017500109A1 (en) | Composition for treating cancerous cells and a method therefor | |
PH12017500430A1 (en) | Solubilized enzyme and uses thereof | |
MX2023004302A (es) | Anticuerpos anti-cd38 y fusiones con interferon alfa-2b atenuado. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued |